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Aims The totally subcutaneous implantable-defibrillator (S-ICD) is a new alternative to the conventional transvenous ICD
system to minimize intravascular lead complications. There are limited data describing the long-term performance of
the S-ICD. This paper presents the first large international patient population collected as part of the EFFORTLESS
S-ICD Registry.
Methods
and results
The EFFORTLESS S-ICD Registry is a non-randomized, standard of care, multicentre Registry designed to collect long-
term, system-related, clinical, and patient reported outcome data from S-ICD implanted patients since June 2009. Follow-
up data are systematically collected over 60-month post-implant including Quality of Life. The study population of 472
patients of which 241 (51%) were enrolled prospectively has a mean follow-up duration of 558 days (range 13–1342
days, median 498 days), 72% male, mean age of 49+18 years (range 9–88 years), 42% mean left ventricular ejection frac-
tion. Complication-free rates were 97 and 94%, at 30 and 360 days, respectively. Three hundred and seventeen spontan-
eous episodes were recorded in 85 patients during the follow-up period. Of these episodes, 169 (53%) received therapy,
93 being for Ventricular Tachycardia/Fibrillation (VT/VF). One patient died of recurrent VF and severe bradycardia.
Regarding discrete VT/VF episodes, first shock conversion efficacy was 88% with 100% overall successful clinical conver-
sion after a maximum of five shocks. The 360-day inappropriate shock rate was 7% with the vast majority occurring for
oversensing (62/73 episodes), primarily of cardiac signals (94% of oversensed episodes).
Conclusion The first large cohort of real-world data from an International patient S-ICD population demonstrates appropriate
system performance with clinical event rates and inappropriate shock rates comparable with those reported for conven-
tional ICDs. Clinical trial registration URL: http://www.clinicaltrials.gov. Unique identifier NCT01085435.
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Introduction
Sudden cardiac death (SCD) occurs in 50 000–70 000 patients
annually in the UK, proportionate numbers of patients in other
European countries and.350 000 patients in the USA.1 Implantable
cardioverter-defibrillators (ICDs) were first introduced into clinical
practice in 19802 and since then multiple randomized, multicentre
trials have shown significant survival benefits in primary and second-
ary prevention populations.3 – 6 Despite the recognized mortality
benefit, there are significant co-morbidities associated with ICD
therapy especially in young primary prevention patients due to the
high incidence of acute and chronic transvenous lead complica-
tions.7,8 These include systemic infections, acute and chronic dis-
placement, pneumothorax, cardiac perforation, and tamponade as
well as inappropriate shocks associated with insulation failure or
lead fractures.9,10 Cumulative data suggest that there may be at
least a 20% risk of transvenous lead failure at 8–10 years post-
implant11,12 and complication rates may also be higher in the paediat-
ric ICD population where long term (5–12 year) reports indicate
rates of at least 40%.13,14 Since complications increase with multiple
procedures, this further places younger ICD patients at considerable
risk of long-term device-related morbidities.
The entirely subcutaneous ICD system (S-ICD System, Cameron
Health/Boston Scientific) was developed to provide an alternative to
the transvenous ICD system, as it is implanted with no transvenous/
epicardial leads. Early studies demonstrating its feasibility and safety
have been published15 as well as small cohorts, single country, and in-
dividual case studies.16–21 However to date, there is no long-term
‘real-world’ data demonstrating the performance of the system in a
multicentre, heterogeneous ICD population. The purpose of the
ongoing Evaluation oF FactORs ImpacTing CLinical Outcome and
Cost EffectiveneSS of the S-ICD (EFFORTLESS S-ICD) Registry is
to document clinical-, system-, and patient-related outcome data
from S-ICD patients implanted since the commercial release of the
S-ICD.22 This paper documents the early results from the EFFORT-
LESS S-ICD Registry.
Methods
Registry design
The EFFORTLESS S-ICD Registry is an observational, non-randomized,
standard of care evaluation currently being conducted in geographies
outside the USA where the S-ICD is approved for use and distribution
since CE Marking in 2009.22 The Registry is conducted according to the
Helsinki Declaration and ISO 14155:2009. Currently seven countries
are actively participating (The Czech Republic, Denmark, Germany,
Italy, The Netherlands, New Zealand and the UK). All the patients
provide informed consent according to National and Institutional regula-
tions. Patients are followed as per Institutional standards for up to
60-months post-implant. All scheduled and unscheduled follow-ups for
the first-year post-implant are recorded, while in years 2–5 post-implant
there is a minimum annual follow-up data requirement (including all
adverse events, spontaneous arrhythmia episodes, and programming
changes). Patients are enrolled prospectively and retrospectively.22
Specific contraindications include class I indications for permanent
pacing, pace-terminable ventricular tachycardia, and previously implanted
functional unipolar pacing system.
Induced and spontaneous episodes
Owing to the variability in acute defibrillation testing protocols at each
clinical site, successful conversion efficacy at implant is defined for the
Registry as at least one successful conversion of an induced ventricular
arrhythmia at ≤80J. Two patients were tested only at energies ,65J,
all other patients had at least one Defibrillation Threshold Test (DFT)
performed at ≥65J. A total of 10 patients had any testing done at
,65J. All spontaneous episodes with documented stored electrogram
evidence were evaluated to determine whether they were ventricular
or supraventricularas opposed tonoise orextra-cardiacphysiological ac-
tivity. Delivery of shock therapy was deemed appropriate if delivered to a
ventricular arrhythmia (VT/VF) at a rate within the programmed condi-
tional or shock zone. Therapy was labelled inappropriate if delivered to
sinus rhythm (e.g. for T-wave oversensing; myocardial potentials;
Electro-magnetic interference (EMI)) or to any supraventricular arrhyth-
mia (SVT) including those with an intrinsic rate within the conditional and
programmed shock zone.
Statistical and data analysis
Baseline demographics and clinical variables, including medical history,
risk factors, co-morbidities, and NYHA functional class for heart failure,
are presented as available. Continuous variables are summarized as
means, standard deviations, medians, and ranges. Categorical variables are
summarizedas frequenciesand percentages. Two-sided P-values for thedif-
ference between prospective and retrospective cohorts were determined
using a Student’s t-test for numerical comparisons and using Pearson’s x2
test for categorical comparisons. Complication-free rates are analysed
using the Kaplan–Meier (KM) estimate. All statistical analyses were per-
formed and independently validated using SAS Enterprise Guide, version
5.1 (SAS 9.3). A two-sided P-value of ,0.05 was considered significant.
Results
Patient demographics
Baseline patient characteristics, medications at the time of initial
implant of the S-ICD System, cardiac history, and co-morbidities
for all enrolled patient are summarized in Table 1. There is a broad
spectrum of patients with a significant proportion of congenital
heart disease, ion channelopathy and non-ischaemic cardiomyopathy
patients, distinguishing this population from standard ICD cohorts.
The characteristics of the three patients withdrawn due to inclu-
sion/exclusion criteria violation are not included in the analysis.
The mean age of patients at implant was 49+18 years (range
9–88 years), the majority was male (72%) and the mean left ven-
tricular ejection fraction was 42%+19%. The majority of study
patients (63%) had a primary prevention indication of which 40%
were ischaemic. Documented co-morbidities included congestive
heart failure (29%), hypertension (24%), ischaemic heart disease
(37%), diabetes (12%), renal disease (9%), and atrial fibrillation (17%).
Sixty-seven patients (15%) had been previously implanted with a trans-
venous ICD system and 13 patients had a concomitant pacemaker.
Patient status
The data set presented reflects the information available at the time
of analysis (data cut-off 23 April 2013) from 472 patients with at least
an enrolment and/or implant data set in the database. Patients were
enrolled between 2 Feb 2011 and 15 Apr 2013 at 29 clinical sites in
Europe and New Zealand (see Figure 1). A total of 241 patients
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(51%) were enrolled prospectively and of these, 232 (96%) were
included in the Quality of Life substudy that will be reported later.
The mean follow-up duration of all implanted patients (n ¼ 456)
was 558 days with a range of 13–1342 days (median ¼ 498 days)
giving a cumulative follow-up duration of 254 578 days. A small
number of the patients have already previously been reported as
part of local, S-ICD experience reports.17 Figure 2 shows the status
of the Retrospective and Prospective patients in the Registry.
Of the patients included, six were withdrawn prior to implant due
to inclusion/exclusion criteria violations (n ¼ 3), patient decision
(n ¼ 1), and investigator decision (n ¼ 2). Nine patients have died
during the course of the Registry (2%). None of the deaths occurred
in the peri-operative period (i.e. within 30-day post-implant) al-
though one remains of unknown cause due to lack of documentation.
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Table 1 Baseline patient characteristics at the time of initial subcutaneous implantable defibrillator system implanta
Characteristic Retrospective Prospective ALL P-valueb
n Value n Value n Value
Age at implant, years 216 47+18 234 51+17 450 49+18 0.02
Age range, years 9–86 15–88 9–88
Male, n (%) 216 149 (69) 234 174 (74) 450 323 (72) 0.21
LVEF, % 164 44+18 184 40+19 348 42+19 0.045
QRS interval, ms 191 104+21 215 109+32 406 107+28 0.07
Primary prevention, n (%) 216 141 (65) 233 141 (61) 449 282 (63) 0.30
Clinical disease, n (%) 214 231 445
Ischaemic cardiomyopathy 70 (33) 96 (42) 166 (37) 0.05
Idiopathic VF 16 (7) 18 (8) 34 (8) 0.90
Inherited channelopathies 36 (17) 24 (10) 60 (13) 0.05
Congenital heart disease 24 (11) 9 (4) 33 (7) 0.003
Non-ischaemic cardiomyopathy 63 (29) 76 (33) 139 (31) 0.43
Dilated 19 24 43
HCM 29 29 58
ARVC 5 12 17
Myocarditis 2 0 2
Non-dilated 2 3 5
Other 6 8 14
Other 5 (2) 8 (3) 13 (3) 0.48
Comorbidities, n (%)
Hypertension 212 50 (24) 234 56 (24) 446 106 (24) 0.93
Atrial fibrillation 209 27 (13) 233 49 (21) 442 76 (17) 0.01
Congestive heart failure 211 53 (25) 232 75 (32) 443 128 (29) 0.09
NYHA I 11 13 24
NYHA II 19 33 52
NYHA III 9 25 34
Diabetes 210 19 (9) 234 34 (15) 444 53 (12) 0.08
Kidney disease 210 14 (7) 233 25 (11) 443 39 (9) 0.13
Concomitant pacemaker 214 5 (2) 233 8 (3) 447 13 (3) 0.49
Previous transvenous ICD 214 30 (14) 233 37 (16) 447 67 (15) 0.58
Cardiac medications, n (%) 214 167 (78) 234 200 (86) 448 367 (82) 0.04
Beta-blocker 125 (75) 155 (78) 280 (76) 0.09
ACE/ARBs 98 (59) 124 (62) 222 (61) 0.13
Diuretic 71 (43) 91 (46) 162 (44) 0.21
Anticoagulant/antiplatelet 98 (59) 124 (62) 222 (61) 0.13
Statins/other lipid lowering 31 (19) 55 (28) 86 (23) 0.02
ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker, ARVC, arrhythmogenic right ventricular dysplasia with risk for sudden cardiac death; HCM, hypertrophic
cardiomyopathy; ICD, implantable cardioverter-defibrillator, LVEF, left ventricular ejection fraction, NYHA, New York Heart Association heart failure classification, S-ICD,
subcutaneous implantable cardioverter-defibrillator; VF, ventricular fibrillation.
aValues are number of patients n(percentage, %) or mean+ standard deviation unless otherwise noted.
bP-value computed for difference between prospective and retrospective cohorts.
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Of the remaining 8 patients, 4 died from pump failure, 1 from kidney
disease, 1 from respiratory failure, and 1 from bronchopneumonia and
stroke secondary to heart failure. One patient died after an apparent
extended period of asystole/bradycardia followed by an appropriately
detected and treated VF episode that failed to convert. The patient
received an additional 11 shocks, none of which was able to convert
the arrhythmia. In this patient, the defibrillation test directly after
implant had been successful. None of the deaths has been reported
to be related to the S-ICD system or implant procedure.
Explants have been documented in 17 patients (3.7%) due to infec-
tion (n ¼ 8), decubitus/erosion (n ¼ 1), heart transplant (n ¼ 1),
failure to convert induced episodes at initial implant (n ¼ 1), failure
to convert spontaneous episodes (n ¼ 1), inappropriate sensing
(n ¼ 1), elective decision after inappropriate shocks (n ¼ 1), replace-
ment of the S-ICD system by a transvenous ICD system due to recur-
rent VT (n ¼ 2) and patient decision due to pain (n ¼ 1). Additionally,
one patient had the device turned OFF due to T-wave oversensing and
recurrent inappropriate therapy. One-year follow-up was completed
in 294 patients (189 retrospective; 105 prospective) with 143 and 52
retrospective patients reaching 2- and 3-year follow-up, respectively.
Five prospective patients have reached 2-years of follow-up.
Implant procedure
Where procedural information was available, general anaesthesia
was used in the majority of S-ICD implantation procedures (273/
432; 63%) with an average procedure time (‘skin to skin’) of 69+
27 min (median 61 min). No distinction was made in the database
between procedure times that were solely for implant of the
S-ICD vs. those that includedadditional procedures suchas concomi-
tant removal of a transvenous system or implant of a pacemaker.
In the majority of cases where information was available no cardiac
imaging was used for placement of the S-ICD system (310/356; 87%).
Figure 1 EFFORTLESS Subcutaneous Implantable Defibrillator Registry enrolment by country in Europe and Australasia (inset).
Figure 2 Patient flow chart for EFFORTLESS Subcutaneous
Implantable Defibrillator Registry.
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Implant conversion testing
Four hundred and ten of 456 patients had available documented VT/
VF conversion testing data performed either acutelyor within days of
implant. In eight cases information was incomplete, while in nine
patients VT/VF was not inducible. Of the 393 patients with complete
data, in all but 1 patient VT/VF was successfully converted (99.7%).
Seven of these patients had an initial conversion failure that required
one or more procedures to reposition the system to become suc-
cessful. A shock energy of ≤65J was successful in 95% of patients.
The 95% CI for DFT conversion efficacy is 99.7% (99.2, 100%).
Spontaneous episodes
Appropriate therapy
A total of 317 spontaneous episodes in 85 individual patients were
recorded during the follow-up, of which 169 episodes received
therapy in 59 patients (see Table 2 and Figure 3). Of the 145 classified
untreated episodes, 93 were adjudicated as inappropriate sensing, 37
were non-sustained VT/VF, 12 were non-sustained SVT above dis-
crimination zone (three are unclassified).
Non-sustained episodes of VT/VF
There were 37 episodes of non-sustained VT/VF which did not last
longer than the initial detection phase of the device algorithms and
therefore were not treated. Two VT/VF episodes spontaneously
converted after confirmation and charging but prior to delivery of a
shock.
Sustained episodes of VT/VF
Ninety-one episodes (53%) in 33 patients were classified as sustained
VT/VF—51 were discrete episodes (n ¼ 29 patients) and 40 were
episodes recorded during VT/VF ‘storms’ (defined as ≥3 treated
VF/VT episodes within 24 h). Of the 51 discrete episodes receiving
therapy, 45 converted to sinus rhythm either immediately or within
a few seconds after the first shock (type 2 break, n ¼ 3) giving a
first shock conversion efficacy of 88%. In the remaining 6 episodes,
.1 shock was required to achieve cardioversion to sinus rhythm.
The overall shock conversion efficacy per protocol definition of suc-
cessful conversion within one device-defined episode and five shocks
was 96% (49/51 episodes). However, in one patient defined as a
failure per protocol, conversion occurred shortly after the fifth
shock (but outside of the Electrogram storage time) and in the
second, a short period of undersensing resulted in an episode
being ended inappropriately by the device after two failed shocks,
only to be re-initiated immediately after with one subsequent, suc-
cessful shock. Clinically, therefore the discrete VT/VF conversion ef-
ficacy was 100% since all episodes were converted.
Six VT/VF storm events in 4 patients resulted in the 40 episodes.
One renal dialysis patient had multiple VT/VF storm events over a
period of 17-month post-implant and subsequently died due to
pump failure. In one case of a patient with Loeffler’s syndrome, the
VF storm was preceded by a 10 min period of bradycardia (lowest
heart rate of 28/min in the 60 s pre-arrest). The VF that subsequently
developed was not successfully defibrillated, and the patient died.
This unusual patient had obliteration of the RV and LV apices by a
mass and was not deemed suitable for a standard ICD system.
At implant VF had been sensed appropriately and cardioverted at 65J.
Inappropriate shocks
A total of 73 inappropriate shocks were recorded in 32 patients over
an average follow-up of 18 months (360 day inappropriate shock rate
of 7%, Table 2 and Figure 3). The majority of inappropriate shocks was
due to oversensing (85%) most frequently of cardiac signals (94% of
oversensed episodes) mainly consisting of T waves or low amplitude
signals (31 and 53% of cardiac oversensed episodes, respectively). In
fourpatients, inappropriate shocksweredue tonoiseorEMIwhile six
patients had inappropriate therapy due to SVT rates that crossed into
the shock-only zone. There was one episode of discriminator error,
in which morphology was impacted by a clipped signal.
Impact of programming
Four hundred and thirty-one patients had their device programming
documented at implant. Three hundred and fifty-seven (82%) had
dual zone programming and 74 (17%) had single zone shock-only
programming. Supplementary material online, Appendix S1 shows
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
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Table 2 Spontaneous episodes recorded and classified
by the subcutaneous implantable defibrillator system
S-ICD system
performance
Number of
episodes
Number of
patients (%of456)
Therapy delivered 169 59 (13)
Appropriate therapy 93 33 (7.2)
VT/VF discrete
episodes
51 29
VT/VF ‘storm’ episodes 40 4
VT/VF conversion
prior to shock
2 2
Inappropriate therapya 73 32 (7.0)
SVT above
discrimination zone
10 6
Inappropriate sensing
(cardiac)b
58 24
Inappropriate sensing
(non-cardiac)
4 4
VF/SVT discrimination
error
1 1
Rhythm unclassifiedc 3 1
Therapy withheldd 145 61 (13)
Episode unclassifiede 3 3
Total 317 85 (19)
SVT, supraventricular tachyarrhythmia; VF, ventricular fibrillation; VT, ventricular
tachyarrhythmia.
aThree patients had multiple episodes of different types. Two patients had episodes
of both cardiac and non-cardiac inappropriate sensing and one patient had episodes
of cardiac oversensing and discrimination error.
bOversensing due to P-waves, wide QRS, T-waves, low amplitude signal, and
unspecified.
cUnclassified episodes where treatment was provided, but no S-ECG source
documentation was retained in order to make a full classification of the treated
episode.
dAppropriate charge with spontaneous termination of VF/VT, inappropriate charge
for SVT above discrimination zone or inappropriate sensing.
eUnclassified episodes that could not be classified as either treated or un-treated
episodes due to incomplete data at the time of data cut.
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the distribution of all programming at implant. Three hundred sixty-
two patients (84%) were programmed with a shock zone of
≥220 b.p.m. Similar proportions of patients were programmed
with primary (50%) and secondary (39%) sensing vectors and very
few were programmed with the alternative sensing vector (10%).
Almost all the patients (94%) were programmed with gain set at
1×. As previously stated, 32 patients (7.0%) received a total of 73 in-
appropriate shocks. Only nine patients (2%) experienced recurrent
inappropriate shocks following initial interventions (reprogramming
and/or exercise test-guided adjustments and one medication
change). Eight of these nine patients experienced recurrent shocks
with the same underlying cause for the initial shock. Two patients
had the device explanted due to the inability to completely mitigate
inappropriate therapy and one patient had the device programmed
OFF. Dual zone programming had a 6.4% inappropriate shock rate
(23/357) while single zone programming had a 12% rate (9/74)
[P ¼ 0.09, (Pearson’s x2 test)]. The former prevented all but one
inappropriate shock for AF/SVT. Supplementary material online,
Appendix S2 shows the programming at the time of inappropriate
shock for each episode.
Time to therapy
Time to therapy was defined as the interval starting 2000 ms after the
last induction artefact and ending at the onset of the shock deflection
on a standard ECG recording. Owing to the limited availability of data
for retrospective patients, it was only recorded for inductions
performed in prospectively enrolled patients and for spontaneous
episodes where the calculation was made by Cameron Health/
Boston Scientific from the electrogram stored in the device. Owing
to lack of pre-defined criteria for induction testing, time to therapy
was available from 195 inductions across a range of shock values up
to 80J. Overall the mean (+SD) time to therapy was 15.1 (+3.7)
s which is less meaningful considering the range of shock energies.
Figure 3 Proportion of appropriate and inappropriate therapies and their aetiologies (three other unclassified treated episodes are excluded in
the figure as they that could not be classified as either treated or untreated episodes). Numbers in brackets represent number of patients.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 3 Subcutaneous implantable defibrillator
systemand/or implant procedure-related complications
requiring intervention
Complication Number
of events
Patients
n (%)
Erosion or extrusion of implanted electrode
or pulse generator
4 4 (0.9)
Haematoma 1 1 (0.2)
Failure to convert spontaneous VF episode 1 1 (0.2)
Inability to communicate with device 1 1 (0.2)
Inappropriate shock: oversensing 2 2 (0.4)
Incision/superficial infection 2 2 (0.4)
Near syncope/dizziness/shortness of
breath/confusion
1 1 (0.2)
Pleural effusion 1 1 (0.2)
Pneumothorax 1 1 (0.2)
Premature battery depletion 1 1 (0.2)
Shock delivered for non-VT/VF 1 1 (0.2)
System infection 12 11 (2.4)
Suboptimal electrode position/electrode
movement
5 5 (1.1)
Suboptimal pulse generator position 1 1 (0.2)
Suture discomfort 1 1 (0.2)
Total complications (% of 456) 35 29 (6.4)
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Since the majority of shocks was delivered at 65J, mean time to
therapy for that cohort was calculated independent of the others
and found to be 15.1 (+3.8) s with a range of 7.0–37.0 s. Two
patients had time to therapies ≥30 s. Time to therapy was recorded
for 77 spontaneous VT/VF episodes, of which there were 81 shocks.
The mean time to therapy for spontaneous episodes was 17.5
(+4.4) s with a range of 6.0 to 29.4 s reflecting a slightly longer
charge time for the higher energy shock delivery in the ambulatory
setting. The 95% CI for conversion efficacy of spontaneous episodes
is 96.1% (90.8, 100%).
System-related complications
All clinical events were subclassified into observations (mitigation
without the need for an invasive procedure) or complications (miti-
gation requiring an invasive procedure). In addition, sites were asked
to classify whether a clinical event was related to the S-ICD system
and/or the implant procedure. In the event that a clear relationship
could not be documented but could not be ruled out, a conservative
classification was adopted. At the time of analysis, a total of 129 clin-
ical events (in 92 patients, 21%) were classified as being possibly
related or definitely related to the S-ICD system or the implantation
procedure. Of these, 35/456 (7.7%) were classified as complications
in 29 patients giving a patient complication event rate of 6.4% (4.1,
8.6%) (Table 3).
There were no documented lead fractures or breakages. Four
patients had a documented lead movement, two of which required
no action and two required re-positioning. Fifteen system-related
complications in 14 patients (3%) occurred in the first 30-day post-
implant, which accounts for a peri-operative complication-free rate
of 97%. Figure 4 shows patients’ complication-free system-related
data for the first 360-day post-implant. At 180-day post-implant,
26 patients had 29 documented system- or implantation-related
complications giving a complication-free rate of 94%. At 360-day
post-implant 28patientshad 32documented systemor implantation-
related complications and the complication-free rate was 94%.
Infections
At the time of analysis, a total of 18 patients at 10 different sites had 20
documented infections or suspicions of infection related to the
S-ICD procedure (4%). The 95% CI for total infection rate is 3.9%
(2.2%, 5.7%). In one patient, this was due to a concomitant pacemaker
implant, in one other secondary to capped leads of an explanted
TV-ICD system. In both cases, the S-ICD system was unaffected.
Serious infection leading to S-ICD removal was seen in 10 patients
(explant rate 2.2%). Of note, only three sites had documented recur-
rent infections requiring explantation (in separate patients). For one
site infections appeared to be linked to the timing of renovations of
the surgical suite. For the other two sites, there is no clear relation-
ship between experience and infection with explants occurring
both at ,6 months and .1 year after first implant.
Discussion
Although the TV-ICD system has served us well over the past 30
years, having been implanted in over 1 million patients worldwide,
there remain significant concerns regarding the potential problems
of long-term intravascular lead complications particularly in young
primary prevention patients who may face over 40 years of generator
and lead revisions.8,17,23 This has spurred the endeavour to provide
alternatives to combat what is often considered the ‘Achille’s heal’
of the TV-ICD—the intravascular lead, at least in those patients
not requiring permanent pacing or anti-tachycardia pacing (ATP).
The EFFORTLESS S-ICD Registry was initiated in order to provide
‘real-world’ systematically collected system performance data over
a suitably prolonged period beyond that normally collected in rando-
mized controlled trials, since these are primarily interested in survival
endpoints as opposed to the important details of system perform-
ance. The Registry currently demonstrates that the device is being
successfully implanted in a broad spectrum of patients with 98%
first procedure induced VF conversion efficacy. Furthermore, there
has been 100% overall clinical conversion efficacy of discrete epi-
sodes of spontaneous VT/VF (88% first shock conversion efficacy)
either immediately post-shock or within a few seconds of shock de-
livery. Overall, conversion efficacy of spontaneous episodes is 96.1%
(90.8%CI, 100%).This is equivalent to the FDAInvestigationalDevice
Exemption (IDE)datawhere theconversionefficacy for spontaneous
episodes was 92.1% on the first shock and 37 of 38 (97.4%) with one
or more shocks.24 Furthermore in the context of DFT testing, the
Registry data show similar efficacy to IDE 99.7% (99.2, 100%) vs.
94.7% (with a 95% lower confidence limit of 91.7%). Five of the six
VT/VF storm events were successfully converted by the device.
The patient with Loeffler’s syndrome who did not survive the
cardiac arrest is an unusual indication. As this patient had an
ongoing biopsy-proven inflammatory disease process requiring
steroid therapy, this may have led to elevation of the DFT.
The first shock conversion efficacy of 88% is very much in line with
rates published in TV-ICD and Cardiac Resynchronisation-Defibrilla-
tor (CRT-D) cohorts25,26 which is particularly important considering
the potential differences in the S-ICD patient population, including an
overall average younger age and a high prevalence of non-ischaemic
cardiomyopathies, congenital, and channelopathy patients—all of
whom are historically more difficult to treat with the TV-ICD. The
implant procedure has not been associated with the typical
implant-related complications of haemo/pneumothorax and lead
displacement seen in 2–6% of trial and Registry TV-ICD popula-
tions.27 –31 The only significant complication has been that of
procedure-related infection affecting 4% of patients overall and
resulting inexplant in2%. Infections aremostprobably related topro-
cedural inexperience in terms of appropriate skin preparation,
draping, and suturing associated with this new procedure which
requires an unfamiliar, more surgical approachof left lateral thoracot-
omy skin incision and tunnelling of the lead. However, the learning
curve and shared experience of optimal pre- and peri-operative tech-
nique should mean that this initial complication can be suitably
addressed.17 Indeed in the Cameron Health IDE study,24 once
optimal technique between centres was agreed upon there were
no subsequent infections requiring explant after approximately the
first 100 patients suggesting a problem related to inexperience of a
new implantation technique. The relationship between infections
and experience is less obvious in the EFFORTLESS Registry. It
should also be recognized that infection remains a significant compli-
cation of TV-ICD implantation with acute infections in the first
30-day post-implant ranging between 2 and 4% (Entrust IDE, Canad-
ian ICD Registry, Medicare, Canadian Advisory data) depending upon
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the population of patients (age, co-morbidities) and experience of
the implanting centres. Infections requiring system explantation
range between 1 and 2% for TV-ICDs which is compatible with the
early experience with the S-ICD.
The inappropriate shock rates (7%) are comparable with the
standard TV-ICD registries and trials which range from 4 to
18%.32– 34 However, in contrast to TV systems, the main cause of in-
appropriate shocks with the S-ICD is T-wave oversensing. The S-ICD
has several options for management of inappropriate shocks without
the need for an invasive procedure including reprogramming of the
sensing vector and exercise testing with template updates. Indeed,
the more prolonged detection time and programming of a dual
zone device with SVT discrimination algorithms and conditional
shock zone for higher rates .220/min may have helped to minimize
inappropriate shock therapy and allowed spontaneous VT episodes
to self-terminate as has been recognized in recent studies of modify-
ing VT detection criteria and delaying ATP therapies.33–36 In the
PREPARE trial which prolonged VT detection to 30/40 beats in-
appropriate shocks were reduced to 4% as opposed to 35% over
5 years in SCD-HeFT;6,34 35% of VT’s self-terminated in PainFreeRx
indicating that the strategy of prolonging detection time before
committing to therapy is a reasonable approach supported by this
recent TV-ICD data.37
Comparison with recent cohort studies
This is the largest series of S-ICD patients to be reported to date and
reflects practice across multiple centres worldwide. Two recent
single country series from the Netherlands17 and UK19 reported
Figure 4 Kaplan–Meier analysis for freedom from subcutaneous implantable defibrillator system-related complications for the first 360-day
post-implant.
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upon 118 and 111 patients, respectively. The inappropriate shock
rates were higher, occurring in 13 and 15% of patients and mainly
due to T wave oversensing. This is double the rate observed in this
larger cohort and probably is a reflection of several issues. Firstly,
many of the reported patients were implanted with the device
either prior to its CE mark, or immediately after. Subsequent
updates to the noise detection algorithm occurred as a result of
inappropriate therapy recorded in these early patients. Secondly,
with continued experience there has been an increased recognition
of appropriate patient management prior to device implant including
ensuring there is ideally more than one acceptable sensing vector
during screening; optimising heart rate thresholds for therapy as
well as ECG screening in different postures and during increased
heart rates. Similarly, the higher infection rates requiring explant of
5.8 and 4% vs. 2.2% in this series are most probably a reflection of
increased physician experience and optimization of implant tech-
nique. In none of these series has there been a failure to deliver
therapy in the programmed shock zone for ventricular arrhythmia
although there was one arrhythmic death in the UK cohort.
However, the useof the S-ICD asafirst line therapy in all ICD patients
without the need of pacing will require confirmation in clinical trials
comparing the S-ICD to the TV-ICD which are currently ongoing.38
Limitations
This is a Registry designed to record the real world experience plan-
ning ultimately to recruit 1000 patients with 5 years of follow-up data.
The initial results demonstrate the early outcomes in the first
12 months after system implantation. The issue of long-term device
performance particularly appropriate and safe cardioversion of VF
in daily life as opposed to the controlled confines of a DFT test will
only become clearer with time. The fact that the system performs ef-
fectively at implant is supported by this and the IDE data.24 It is recog-
nized that controversies exist regarding whether DFT testing actually
is appropriate for assessing ICD efficacy and most ICD cardioversion
failures occur in the real-world under conditions of major metabolic
derangement, hypoxia, and ischaemia which are beyond the normal
ranges of standard DFT testing when the patient is in a well oxyge-
nated, sedated state. Despite this, successful DFT at implant has
been employed as an appropriate clinical safety endpoint particularly
for a new technology and an indication of safe system performance as
required by the FDA.
Conclusions
The first large cohort of real-world data from an International patient
S-ICD system population demonstrates appropriate system per-
formance with clinical event rates and inappropriate shock rates
comparable with those reported for conventional ICDs.
Supplementary material
Supplementary material is available at European Heart Journal online.
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